A drug for intractable epilepsy
An intractable, drug technology, applied in the field of drugs and preparations for the treatment of intractable epilepsy, can solve the problems of drug dissolution affecting tablet disintegration, slow action, content reduction, etc., to achieve satisfactory clinical efficacy, improve symptoms, and relieve pain. Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0017] A preparation method of a medicine for treating intractable epilepsy, comprising the steps of:
[0018] (1) Pretreatment of valerian extract:
[0019] Remove fibrous roots and reed heads from 20g of valerian herbal medicine until the water content is less than 2%, grind valerian root into a coarse powder with a diameter of less than 0.3mm with a pulverizer, and use 3-8% ethanol equal to the weight of valerian herb The coarse powder is soaked for 20-28 hours, and then refluxed with 60% ethanol, which accounts for 3 times the weight of the Valerian Chinese herbal medicine, to collect the extract, reduce the pressure, concentrate and recover the ethanol, and finally use 50% ethanol, which accounts for 1.5 times the weight of the Valerian Chinese medicinal material. The extract is refluxed again to extract the extracted extract, the ethanol is recovered, and the valerian extract is collected.
[0020] (2) Preparation of intractable epilepsy drugs:
[0021] Take 200.0g of ...
Embodiment 2
[0023] Drug Stability Experiment for the Treatment of Intractable Epilepsy Prepared by the Invention
[0024] (1) Determination of Nuxychnium powder:
[0025] Refer to the 2010 Chinese Pharmacopoeia Nuxychnium powder content determination method for detection, and at the same time verify the analysis method; verify the precision, linearity, repeatability, stability, etc. to ensure that the analysis is effective. The average content of strychnine was measured as: 0.017mg / tablet; the average content of strychnine was: 0.038mg / tablet. With reference to Pharmacopoeia and clinical medication notice: the consumption of Nuxychnium powder is 0.2-0.6g, and the content of Nuxychnium powder of the present invention is 2.5mg / sheet (strychnine is 0.017mg / sheet, strychnine is 0.038mg / sheet ), the dose is far lower than the Pharmacopoeia and clinical drug standards, and the safety is better.
[0026] (2) Determination of phenobarbital content:
[0027] Detect with reference to the 2010 Ch...
Embodiment 3
[0031] Acute Toxicity Test Study of the Medicine for Treating Intractable Epilepsy Prepared by the Invention
[0032] 1. Take 50 healthy mice with a body weight that meets the requirements, weighing 17-22g, 10 in each group, both male and female, provided by the Hubei Medical Experimental Animal Center. Divided into A, B, C, D, E5 groups. Test product The medicine (the specification is 0.4g / sheet) of the present invention is provided by the preparation room of Renhe Hospital, Three Gorges University, and the preparation approval number is No. DX07-011 of Eyao Zhizi (2001), and it is prepared with distilled water before use. 0.08g / L test suspension (stock solution). According to the pre-test results, take the suspension (stock solution) for testing and the diluents whose mass concentration is 0.068, 0.058, 0.049, 0.042g / L diluted with distilled water in equal proportion before use.
[0033] 2. The mice in each group were intragastrically administered at a dose of 0.4ml per 2...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com